fbpx

Neoleukin Therapeutics Inc

NLTX

$

Closing

1D

YTD

Exchange

Sector

Market cap

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Growth

119.60

Company Profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The Company uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The Company operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The Company’s primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.